Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 01/05/2018

Debbie Rigby takes a look at the latest in research news Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT) A 24-week randomised controlled, comparative effectiveness trial comparing extended-release naltrexone, an opioid antagonist, and sublingual buprenorphine-naloxone, a partial opioid agonist has concluded these medicines indicated for opioid dependence are equally safe and

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

What does the future look like for CWH/Sigma shareholders?

Yeh but CWH's entire business model is to go to areas with low rent and charge below cost prescriptions and…

Bob Tran

What does the future look like for CWH/Sigma shareholders?

if they can't grow internally they can easily acquire other store and distribution centre and shareholder would be more than…

viknesh bramasta

What does the future look like for CWH/Sigma shareholders?

Ponraj unlike Coles CWH sell medications LOL - if they can't grow internally they can easily acquire other store and…

viknesh bramasta

What does the future look like for CWH/Sigma shareholders?

Undervalued. With the data Sigma have on your purchasing (even if not primary supplier), combined with what they receive from…

Justin Levine

Research Roundup

Previous Setting the agenda

Next Mind-bending drugs and devices: can they make us smarter?

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous Setting the agenda

Next Mind-bending drugs and devices: can they make us smarter?

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.